JAK2 and myeloproliferative neoplasm: At multivariate analysis restricted to MPN patients presenting with SVT, molecular high-risk was associated with increased risk of a new thrombotic event of any type (HR 5.8, 95% CI 1.4–24.0, p = 0.01) after adjustment by age (p not significant) and JAK2 allele burden (p not significant).